HERNEXEOS Lung Cancer Treatment: First FDA Appr...

By HEOR Staff Writer

March 2, 2026

FDA Greenlights HERNEXEOS Lung Cancer Treatment as First-Line Option HERNEXEOS lung cancer treatment (zongertinib tablets), developed by
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...